Post-Marketing Surveillance of Humira Injection in Korean JIA Patients Under the New-Drug Re-examination
Phase of Trial: Phase IV
Latest Information Update: 28 Jun 2017
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions
- Sponsors AbbVie
- 04 May 2016 Status changed from recruiting to completed.
- 04 Nov 2015 Planned end date changed from 1 Apr 2016 to 1 May 2016, as reported by ClinicalTrials.gov.
- 04 Nov 2015 Planned primary completion date changed from 1 Apr 2016 to 1 May 2016, as reported by ClinicalTrials.gov.